These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26672965)

  • 1. TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2.
    Tamada T; Shinmi D; Ikeda M; Yonezawa Y; Kataoka S; Kuroki R; Mori E; Motoki K
    Sci Rep; 2015 Dec; 5():17936. PubMed ID: 26672965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
    Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
    Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody.
    Feng Y; Xiao X; Zhu Z; Dimitrov DS
    MAbs; 2010; 2(5):565-70. PubMed ID: 20581445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of p38 Activation and Mitochondria in Death of Human Leukemia Cells Induced by an Agonistic Human Monoclonal Antibody Fab Specific to TRAIL Receptor 1.
    Lee YR; Hwang E; Jang YJ
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.
    Dobson CL; Main S; Newton P; Chodorge M; Cadwallader K; Humphreys R; Albert V; Vaughan TJ; Minter RR; Edwards BM
    MAbs; 2009; 1(6):552-62. PubMed ID: 20068388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity.
    Secchiero P; Sblattero D; Chiaruttini C; Melloni E; Macor P; Zorzet S; Tripodo C; Tedesco F; Marzari R; Zauli G
    Int J Immunopathol Pharmacol; 2009; 22(1):73-83. PubMed ID: 19309554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.
    Natoni A; MacFarlane M; Inoue S; Walewska R; Majid A; Knee D; Stover DR; Dyer MJ; Cohen GM
    Br J Haematol; 2007 Nov; 139(4):568-77. PubMed ID: 17922877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Mice With Humanized Livers Demonstrate Human-Specific Hepatotoxicity Caused by a Therapeutic Antibody Against TRAIL-Receptor 2/Death Receptor 5.
    Nihira K; Nan-Ya KI; Kakuni M; Ono Y; Yoshikawa Y; Ota T; Hiura M; Yoshinari K
    Toxicol Sci; 2019 Jan; 167(1):190-201. PubMed ID: 30202993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
    Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
    Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a novel fully human monovalent antigen-binding fragment on the survival of cancer cell lines.
    Kwon YS; Lee YR; Kim YS; Lee HW; Jang YJ
    Oncol Rep; 2007 Aug; 18(2):513-7. PubMed ID: 17611678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity.
    Lee SH; Park DW; Sung ES; Park HR; Kim JK; Kim YS
    Mol Immunol; 2010 Jan; 47(4):816-24. PubMed ID: 19864027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
    Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
    Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
    Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
    Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
    Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
    Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.
    Graves JD; Kordich JJ; Huang TH; Piasecki J; Bush TL; Sullivan T; Foltz IN; Chang W; Douangpanya H; Dang T; O'Neill JW; Mallari R; Zhao X; Branstetter DG; Rossi JM; Long AM; Huang X; Holland PM
    Cancer Cell; 2014 Aug; 26(2):177-89. PubMed ID: 25043603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.
    Strekalova E; Malin D; Good DM; Cryns VL
    Clin Cancer Res; 2015 Jun; 21(12):2780-91. PubMed ID: 25724522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
    Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
    Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel humanized anti-tumor necrosis factor-related apoptosis-inducing ligand-R2 monoclonal antibody induces apoptotic and autophagic cell death.
    Chen L; Qiu Y; Hao Z; Cai J; Zhang S; Liu Y; Zheng D
    IUBMB Life; 2017 Sep; 69(9):735-744. PubMed ID: 28748573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
    Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
    Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis.
    Mori E; Thomas M; Motoki K; Kataika S
    FEBS Lett; 2005 Oct; 579(24):5379-84. PubMed ID: 16199041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.